QQQ   425.99 (+0.04%)
AAPL   167.31 (-0.41%)
MSFT   408.68 (-0.77%)
META   508.55 (+2.91%)
GOOGL   156.51 (+0.67%)
AMZN   181.37 (+0.05%)
TSLA   149.94 (-3.54%)
NVDA   855.17 (+1.76%)
AMD   155.66 (+1.06%)
NIO   4.01 (+2.56%)
BABA   69.12 (+0.44%)
T   16.18 (+0.37%)
F   12.07 (+0.25%)
MU   112.87 (-2.97%)
GE   156.20 (+0.34%)
CGC   7.95 (+22.50%)
DIS   113.50 (+0.50%)
AMC   2.93 (-1.68%)
PFE   25.29 (-0.51%)
PYPL   62.44 (-1.30%)
XOM   118.89 (+0.22%)
QQQ   425.99 (+0.04%)
AAPL   167.31 (-0.41%)
MSFT   408.68 (-0.77%)
META   508.55 (+2.91%)
GOOGL   156.51 (+0.67%)
AMZN   181.37 (+0.05%)
TSLA   149.94 (-3.54%)
NVDA   855.17 (+1.76%)
AMD   155.66 (+1.06%)
NIO   4.01 (+2.56%)
BABA   69.12 (+0.44%)
T   16.18 (+0.37%)
F   12.07 (+0.25%)
MU   112.87 (-2.97%)
GE   156.20 (+0.34%)
CGC   7.95 (+22.50%)
DIS   113.50 (+0.50%)
AMC   2.93 (-1.68%)
PFE   25.29 (-0.51%)
PYPL   62.44 (-1.30%)
XOM   118.89 (+0.22%)
QQQ   425.99 (+0.04%)
AAPL   167.31 (-0.41%)
MSFT   408.68 (-0.77%)
META   508.55 (+2.91%)
GOOGL   156.51 (+0.67%)
AMZN   181.37 (+0.05%)
TSLA   149.94 (-3.54%)
NVDA   855.17 (+1.76%)
AMD   155.66 (+1.06%)
NIO   4.01 (+2.56%)
BABA   69.12 (+0.44%)
T   16.18 (+0.37%)
F   12.07 (+0.25%)
MU   112.87 (-2.97%)
GE   156.20 (+0.34%)
CGC   7.95 (+22.50%)
DIS   113.50 (+0.50%)
AMC   2.93 (-1.68%)
PFE   25.29 (-0.51%)
PYPL   62.44 (-1.30%)
XOM   118.89 (+0.22%)
QQQ   425.99 (+0.04%)
AAPL   167.31 (-0.41%)
MSFT   408.68 (-0.77%)
META   508.55 (+2.91%)
GOOGL   156.51 (+0.67%)
AMZN   181.37 (+0.05%)
TSLA   149.94 (-3.54%)
NVDA   855.17 (+1.76%)
AMD   155.66 (+1.06%)
NIO   4.01 (+2.56%)
BABA   69.12 (+0.44%)
T   16.18 (+0.37%)
F   12.07 (+0.25%)
MU   112.87 (-2.97%)
GE   156.20 (+0.34%)
CGC   7.95 (+22.50%)
DIS   113.50 (+0.50%)
AMC   2.93 (-1.68%)
PFE   25.29 (-0.51%)
PYPL   62.44 (-1.30%)
XOM   118.89 (+0.22%)
Free Trial

Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
OncoCyte Co. stock logo
OCX
OncoCyte
$2.57
-0.8%		$2.95
$2.08
▼
$6.20
$21.23M0.848,121 shs22,393 shs
12 Stocks Corporate Insiders are Abandoning Cover
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
OncoCyte Co. stock logo
OCX
OncoCyte
-5.82%-11.60%-14.24%-21.75%-56.83%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
OncoCyte Co. stock logo
OCX
OncoCyte
1.7093 of 5 stars		3.31.00.00.02.92.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
OncoCyte Co. stock logo
OCX
OncoCyte
2.50
Moderate Buy$3.9051.75% Upside

Current Analyst Ratings

Latest OCX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/17/2024
OncoCyte Co. stock logo
OCX
OncoCyte
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingEqual Weight ➝ Equal Weight$4.00
4/15/2024
OncoCyte Co. stock logo
OCX
OncoCyte
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingSpeculative Buy ➝ Speculative Buy$5.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
OncoCyte Co. stock logo
OCX
OncoCyte
$1.50M14.15$0.83 per share3.08$5.78 per share0.44

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
OncoCyte Co. stock logo
OCX
OncoCyte
-$27.78MN/A0.00∞N/A-3,923.58%-77.26%-33.66%5/9/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
OncoCyte Co. stock logo
OCX
OncoCyte
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
OncoCyte Co. stock logo
OCX
OncoCyte
N/A
2.11
2.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
OncoCyte Co. stock logo
OCX
OncoCyte
55.35%

Insider Ownership

CompanyInsider Ownership
OncoCyte Co. stock logo
OCX
OncoCyte
1.94%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
OncoCyte Co. stock logo
OCX
OncoCyte
758.26 million8.10 millionNo Data

OCX Headlines

SourceHeadline
OncoCyte (NASDAQ:OCX) Now Covered by StockNews.comOncoCyte (NASDAQ:OCX) Now Covered by StockNews.com
americanbankingnews.com - April 18 at 2:30 AM
OncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs Buys 3,390 SharesOncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs Buys 3,390 Shares
americanbankingnews.com - April 16 at 6:58 AM
OncoCyte Co. (NASDAQ:OCX) Director Andrew Arno Acquires 33,898 Shares of StockOncoCyte Co. (NASDAQ:OCX) Director Andrew Arno Acquires 33,898 Shares of Stock
americanbankingnews.com - April 16 at 5:44 AM
OncoCyte (NASDAQ:OCX) Given Speculative Buy Rating at BenchmarkOncoCyte (NASDAQ:OCX) Given Speculative Buy Rating at Benchmark
americanbankingnews.com - April 16 at 4:50 AM
OncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in StockOncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in Stock
insidertrades.com - April 16 at 4:46 AM
OncoCyte Co. (NASDAQ:OCX) Major Shareholder Broadwood Partners, L.P. Buys 2,420,000 Shares of StockOncoCyte Co. (NASDAQ:OCX) Major Shareholder Broadwood Partners, L.P. Buys 2,420,000 Shares of Stock
americanbankingnews.com - April 16 at 4:18 AM
OncoCyte Corporation (OCX) Q4 2023 Earnings Call TranscriptOncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript
seekingalpha.com - April 13 at 10:47 PM
Q4 2023 OncoCyte Corp Earnings CallQ4 2023 OncoCyte Corp Earnings Call
finance.yahoo.com - April 13 at 1:38 AM
OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023
investorplace.com - April 12 at 12:00 PM
Top 3 Health Care Stocks That May Collapse In Q2Top 3 Health Care Stocks That May Collapse In Q2
msn.com - April 12 at 10:36 AM
OncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayOncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
finanznachrichten.de - April 12 at 10:10 AM
S&P Futures Tick Lower as Investors Digest Big Bank EarningsS&P Futures Tick Lower as Investors Digest Big Bank Earnings
msn.com - April 12 at 10:10 AM
S&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank EarningsS&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank Earnings
msn.com - April 12 at 7:32 AM
Oncocyte announces $15.8 mln private placement of securitiesOncocyte announces $15.8 mln private placement of securities
msn.com - April 12 at 7:32 AM
ONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTSONCOCYTE REPORTS Full Year 2023 FINANCIAL RESULTS
prismmediawire.com - April 12 at 6:00 AM
Oncocyte Reports Full Year 2023 Financial ResultsOncocyte Reports Full Year 2023 Financial Results
globenewswire.com - April 12 at 6:00 AM
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
prismmediawire.com - April 11 at 9:48 PM
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq RulesOncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
globenewswire.com - April 11 at 9:46 PM
Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayOncocyte and Bio-Rad Partner on Global Launch of Transplant Assay
globenewswire.com - April 11 at 5:30 PM
Heres what Wall Street expects from Oncocytes earningsHere's what Wall Street expects from Oncocyte's earnings
markets.businessinsider.com - April 11 at 12:51 PM
ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ONCOCYTE TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS 
prismmediawire.com - April 9 at 4:05 PM
Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial ResultsOncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results
globenewswire.com - April 9 at 4:05 PM
NeuroBo stock jumps 14% on weight-loss drug updateNeuroBo stock jumps 14% on weight-loss drug update
msn.com - February 29 at 10:17 AM
OncoCyte Stock (NASDAQ:OCX), Short Interest ReportOncoCyte Stock (NASDAQ:OCX), Short Interest Report
benzinga.com - February 24 at 8:37 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

OncoCyte logo

OncoCyte

NASDAQ:OCX
OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.